Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 16/20 | 0.50 |
| ▸ | GIPR | P48546 | 13/20 | 0.50 |
| ▸ | GLP1R | P43220 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.42 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.42 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.42 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.42 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.42 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.42 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.42 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.42 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655178 | 0.89 | GCGR (0.56) | GCGRGIPRGLP1REPHX2TMEM97 | |
| SCHEMBL2660016 | 0.81 | GCGR (0.51) | GCGRGIPRGLP1REPHX2TMEM97 | |
| SCHEMBL6755529 | 0.80 | GCGR (0.67) | GCGRGIPRGLP1REPHX2TMEM97 | |
| SCHEMBL2650667 | 0.79 | LSS (0.58) | GCGRGIPRGLP1REPHX2TMEM97 | |
| SCHEMBL2653796 | 0.78 | GCGR (0.64) | GCGRGIPRGLP1REPHX2ADCY6 | |
| SCHEMBL2662590 | 0.78 | GCGR (0.62) | GCGRGIPRGLP1REPHX2TMEM97 | |
| SCHEMBL2654691 | 0.76 | GCGR (0.68) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL2654717 | 0.75 | GCGR (0.55) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL2655058 | 0.74 | GCGR (0.66) | GCGRGIPRGLP1RADCY6ADCY3 | |
| SCHEMBL2653012 | 0.74 | ESRRG (0.55) | GCGRGIPREPHX2ADCY6ADCY3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.